ClinicalTrials.gg

Program

bexmarilimab

Also written as “bexmarilimab (1mg/kg)”, “bexmarilimab (3mg/kg)” and “Bexmarilimab”.

Its studies are mostly in Neoplasms · Leukemia, Myeloid, Acute · Carcinoma, Renal Cell, led by Faron Pharmaceuticals.

Furthest: phase 2, since Oct 23, 20184 company-led studies, 2 open or runningNext primary completion: Mar 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Faron Pharmaceuticals42 open or runningphase 2since Oct 23, 2018Oct 23, 2018Mar 2027phase 2 · NCT05428969

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 23, 2018First study: phase 2 study in NeoplasmsFirst studyNCT03733990 · 216 enrolled · United States, Finland, France and more
  2. Oct 22, 2021Phase 2 study in Carcinoma, Renal CellNCT05104905 · Finland
  3. Jun 15, 2022Phase 2 study in Leukemia, Myeloid, AcuteNCT05428969 · 181 enrolled · United States, Finland, United Kingdom
  4. Apr 27, 2026Phase 2 study in NeoplasmsNCT07672769 · 90 planned · United States, Czechia, Finland and more

Ahead

  1. Mar 2027Primary completion: phase 2 study in Leukemia, Myeloid, AcuteNCT05428969
  2. Nov 2027Primary completion: phase 2 study in NeoplasmsNCT07672769

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07672769Neoplasms · United States, Czechia, Finland and more2RecruitingNov 202790
NCT05428969Leukemia, Myeloid, Acute · United States, Finland, United Kingdom2Active, not recruitingMar 2027181
NCT05104905Carcinoma, Renal Cell · Finland2WithdrawnJan 28, 20220
NCT03733990Neoplasms · United States, Finland, France and more2CompletedSep 6, 2023216

How it is read

Names in the registry

  • “bexmarilimab (1mg/kg)”, 1 entry
  • “bexmarilimab (3mg/kg)”, 1 entry
  • “Bexmarilimab”, 1 entry
  • “FP-1305 (bexmarilimab)”, 1 entry
  • “bexmarilimab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.